Johnson S P P P T

This document summarizes two studies comparing the efficacy of Lovaza and nicotinic acid in treating severe hypertriglyceridemia. Study 1 was a randomized controlled trial that found Lovaza reduced triglyceride levels by 45% with fewer side effects than nicotinic acid. Study 2 was an open-label extension trial that found nicotinic acid reduced triglyceride levels by 28% but was associated with more side effects requiring hospitalization compared to Lovaza. Both studies concluded that Lovaza more effectively lowers triglycerides and is better tolerated than nicotinic acid for patients with severe hypertriglyceridemia.